IL-17E is assoiated with Virulizin, I am a non-scientist so won't try to discuss the relationship.
"TORONTO, ONTARIO, Feb. 24, 2010 (Marketwire) -- Lorus Therapeutics Inc. (TSX:LOR)("Lorus"), a biopharmaceutical company specializing in the research and development of pharmaceutical products and technologies for the management of cancer, today announced a publication demonstrating the antitumor activity of a novel cytokine interleukin 17E (IL-17E). The article entitled "IL-17E, a pro-inflammatory cytokine, has antitumor efficacy against several tumor types in vivo" was published in the peer-reviewed journal, Cancer Immunology Immunotherapy and is currently available online on the Journal's website.
In this article, Lorus' scientists demonstrated the antitumor effects of IL-17E alone and in combination with a number of approved anticancer agents in preclinical models. The studies showed that IL-17E alone had potent antitumor activity in a number of solid tumors, including melanoma, breast, colon, pancreatic, and non-small cell lung cancers. In combination studies, IL-17E was compatible with a wide variety of approved anticancer drugs, including Avastin, Tarceva, Taxol, Cisplatin, Dacarbazine, Irinotecan, and Gemzar. Furthermore, the combination of IL-17E with each of these anticancer agents showed greater anticancer efficacy than either agent alone without additional toxicity."
Norman
The article also provided data on the mechanism of anticancer activity for IL-17E, showing that IL-17E activates the immune system, specifically acting on eosinophils and B cells. IL-17E stimulated the production of eosinophils and increased the infiltration of eosinophils into tumors in association with antitumor response. The studies also showed that B cells were necessary for IL-17E antitumor efficacy.
Norman
Recent APTO News
- Form 8-K - Current report • Edgar (US Regulatory) • 09/06/2024 08:15:12 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 09/05/2024 08:20:21 PM
- Aptose Announces Results from Special Meeting of Shareholders • GlobeNewswire Inc. • 09/05/2024 08:15:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 08/30/2024 08:35:07 PM
- Aptose Receives $10 Million Through a Facility Agreement with Hanmi; Negotiating Future Collaboration Agreement with Hanmi to Jointly Develop Tuspetinib • GlobeNewswire Inc. • 08/30/2024 08:30:02 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 08/15/2024 08:35:12 PM
- Aptose Announces Adjournment of its Special Meeting of Shareholders • GlobeNewswire Inc. • 08/15/2024 08:30:00 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 08/08/2024 09:22:28 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 08/08/2024 09:15:13 PM
- Aptose Reports Results for the Second Quarter 2024 • GlobeNewswire Inc. • 08/08/2024 09:06:51 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 07/26/2024 08:30:11 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 07/19/2024 09:00:14 PM
- Aptose Announces Receipt of Deficiency Notice from Nasdaq • GlobeNewswire Inc. • 07/19/2024 09:00:00 PM
- Form DEF 14A - Other definitive proxy statements • Edgar (US Regulatory) • 07/17/2024 03:43:45 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 06/14/2024 11:40:15 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 06/03/2024 08:35:17 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 06/03/2024 02:32:05 PM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 06/03/2024 10:05:42 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 05/31/2024 12:05:15 PM
- Form DEF 14A - Other definitive proxy statements • Edgar (US Regulatory) • 05/15/2024 03:47:00 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 05/14/2024 09:06:23 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 05/14/2024 08:15:19 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 05/10/2024 03:35:32 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 05/06/2024 08:45:13 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 03/01/2024 10:00:16 PM
VHAI - Vocodia Partners with Leading Political Super PACs to Revolutionize Fundraising Efforts • VHAI • Sep 19, 2024 11:48 AM
Dear Cashmere Group Holding Co. AKA Swifty Global Signs Binding Letter of Intent to be Acquired by Signing Day Sports • DRCR • Sep 19, 2024 10:26 AM
HealthLynked Launches Virtual Urgent Care Through Partnership with Lyric Health. • HLYK • Sep 19, 2024 8:00 AM
Element79 Gold Corp. Appoints Kevin Arias as Advisor to the Board of Directors, Strengthening Strategic Leadership • ELMGF • Sep 18, 2024 10:29 AM
Mawson Finland Limited Further Expands the Known Mineralized Zones at Rajapalot: Palokas step-out drills 7 metres @ 9.1 g/t gold & 706 ppm cobalt • MFL • Sep 17, 2024 9:02 AM
PickleJar Announces Integration With OptCulture to Deliver Holistic Fan Experiences at Venue Point of Sale • PKLE • Sep 17, 2024 8:00 AM